<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975347</url>
  </required_header>
  <id_info>
    <org_study_id>313512</org_study_id>
    <nct_id>NCT04975347</nct_id>
  </id_info>
  <brief_title>Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank</brief_title>
  <official_title>Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephanie B. Seminara, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the effects of opioid antagonists on the&#xD;
      hypothalamic-pituitary-gonadal axis in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assignment: Each study subject will serve as their own control.&#xD;
&#xD;
      Delivery of Interventions:&#xD;
&#xD;
        -  Prior to the study visit, subjects will undergo a review of their medical history and&#xD;
           screening laboratories.&#xD;
&#xD;
        -  On the days of the inpatient study, the subjects will&#xD;
&#xD;
             -  Day 1: Undergo frequent blood sampling for 19 hours; the total amount of blood&#xD;
                drawn during the visit does not exceed maximum blood draw volumes per institutional&#xD;
                guidelines&#xD;
&#xD;
                  -  Receive 3 kisspeptin intravenous (IV) boluses&#xD;
&#xD;
                  -  Receive 1 Gonadotropin Releasing Hormone (GnRH) IV bolus&#xD;
&#xD;
             -  Day 2: Undergo q10 min blood sampling for 13 hours&#xD;
&#xD;
                  -  Receive a naloxone bolus followed by a naloxone infusion&#xD;
&#xD;
                  -  Receive 3 kisspeptin IV boluses&#xD;
&#xD;
                  -  Receive 1 GnRH IV bolus&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average change in Luteinizing Hormone (LH) pulse frequency</measure>
    <time_frame>35 hours</time_frame>
    <description>change in LH pulse frequency before and during naloxone infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average change in LH pulse amplitude</measure>
    <time_frame>35 hours</time_frame>
    <description>change in LH pulse amplitude before and during naloxone infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Reproductive Disorders</condition>
  <arm_group>
    <arm_group_label>kisspeptin, GnRH, naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV administration of kisspeptin 112-121; six boluses in a 35-hour period. IV administration of GnRH; two boluses in a 35-hour period. IV administration of naloxone; one bolus and an infusion over a 13-hour period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>kisspeptin 112-121</intervention_name>
    <description>Six IV doses of kisspeptin 112-121</description>
    <arm_group_label>kisspeptin, GnRH, naloxone</arm_group_label>
    <other_name>metastin 45-54</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH</intervention_name>
    <description>Two IV doses of GnRH</description>
    <arm_group_label>kisspeptin, GnRH, naloxone</arm_group_label>
    <other_name>gonadotropin-releasing hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>One bolus and one infusion of naloxone</description>
    <arm_group_label>kisspeptin, GnRH, naloxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Normal puberty with respect to onset and pace&#xD;
&#xD;
          -  No history of chronic disease&#xD;
&#xD;
          -  No prescription medications for at least 2 months except for seasonal allergy&#xD;
             medications&#xD;
&#xD;
          -  No illicit drug use&#xD;
&#xD;
          -  No excessive alcohol consumption (&lt; 10 drinks/week)&#xD;
&#xD;
          -  No history of a medication reaction requiring emergency medical care&#xD;
&#xD;
          -  No difficulty with blood draws&#xD;
&#xD;
          -  Not currently seeking fertility&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 18.5 and &lt; 30 kg/m2&#xD;
&#xD;
          -  Normal blood pressure (BP) (systolic BP &lt; 140 mm Hg, diastolic &lt; 90 mm Hg)&#xD;
&#xD;
          -  White blood cell, platelet counts, prolactin, and Thyroid Stimulating Hormone (TSH)&#xD;
             between 90% of the lower limit and 110% of the upper limit of the reference range&#xD;
&#xD;
          -  Normal hemoglobin&#xD;
&#xD;
          -  Blood urea nitrogen (BUN), creatinine not elevated&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), alanine transaminase (ALT) &lt;2x upper limit of&#xD;
             reference range&#xD;
&#xD;
          -  Normal levels of LH, Follicle Stimulating Hormone (FSH), and sex steroids (estradiol&#xD;
             or testosterone)&#xD;
&#xD;
          -  Negative urine drug screening panel&#xD;
&#xD;
          -  For men:&#xD;
&#xD;
               -  Normal erectile and ejaculatory function by report, no history of reproductive&#xD;
                  disorders (i.e. no history of cryptorchidism)&#xD;
&#xD;
               -  Testicular volume &gt;15 ml by Prader orchidometer&#xD;
&#xD;
          -  For women:&#xD;
&#xD;
               -  Menstrual cycles between 25 and 35 days in duration, at least 11 periods/year,&#xD;
                  with no more than 5 days variability in cycle duration&#xD;
&#xD;
               -  No oral contraceptives for at least 1 month&#xD;
&#xD;
               -  No evidence for androgen excess (hirsutism or acne)&#xD;
&#xD;
               -  Not breastfeeding and not pregnant&#xD;
&#xD;
               -  Negative serum human chorionic gonadotropin (hCG) pregnancy test at the time of&#xD;
                  screening, (additional urine pregnancy test will be conducted prior to drug&#xD;
                  administration)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stephanie B. Seminara, MD</investigator_full_name>
    <investigator_title>Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>kisspeptin</keyword>
  <keyword>naloxone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

